查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1992389

支气管痉挛治疗市场：2026-2032年全球市场预测（按治疗方法、药物类别、给药途径、分销管道和最终用户划分）

Bronchial Spasms Treatment Market by Treatment Type, Drug Class, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，支气管痉挛治疗市场价值将达到 3.2386 亿美元，到 2026 年将成长至 3.3725 亿美元，到 2032 年将达到 4.4077 亿美元，年复合成长率为 4.50%。

主要市场统计数据
基准年 2025 3.2386亿美元
预计年份：2026年 3.3725亿美元
预测年份 2032 4.4077亿美元
复合年增长率 (%) 4.50%

对现代支气管痉挛治疗路径中的临床挑战、治疗方法多样性、患者需求和相关人员决策因素进行了权威概述。

支气管痉挛是一种阵发性且常反覆发作的疾病，其特征是下呼吸道收缩，对患者和临床诊疗带来沉重负担。其病理生理机转涉及气道高反应性，伴随平滑肌收缩、黏膜水肿和多种发炎过程，因此需要采取快速缓解症状和预防復发的策略。临床医师必须平衡急性期治疗和长期控制气道炎症，这种平衡会影响不同医疗机构的治疗方法选择。因此，治疗方案包括以器械为基础的给药系统、注射生物製剂和全身性用药，以及针对不同作用机制的口服药物。

精准医疗、先进的吸入平台和不断发展的护理模式如何重塑支气管痉挛治疗的临床选择和商业性路径。

近年来，支气管痉挛的治疗发生了变革性变化，这得益于治疗方法和医疗服务模式的同步进步。在治疗方面，临床工具箱不断扩充，包括精准生物製药和优化的吸入技术，从而能够针对不同表型的患者群体进行更个人化的干预。与药物治疗的进步相辅相成的是，粉剂和气雾剂给药装置的创新，这些创新强调给药的精准性、易用性和对患者用药依从性的支持，共同改变了临床医生选择和处方治疗方法的方式。数位化用药依从性工具和远端监测的整合进一步强化了这些变革，使得患者能够在独立的临床环境之外进行长期管理。

评估 2025 年美国关税变化对支气管痉挛治疗的供应链、製造经济、筹资策略和临床连续性的实际影响。

美国2025年实施的关税调整的累积影响正对支气管痉挛治疗生态系统中的所有相关人员产生实际影响。由于关税上涨，原料药、计量阀和特殊聚合物等医疗设备组件以及进口生产设备的成本增加，给生产效率带来了上行压力。为此，赞助商和契约製造製造商正试图透过审查与供应商的合约、加快双重采购策略以及在某些情况下将关键组装流程转移到更靠近主要市场的地方来降低贸易政策变化带来的风险。

详细的細項分析将治疗方法、剂型、药物类别、通路和医疗保健环境与影响临床引入和商业化的因素联繫起来。

精细化的细分观点清楚地展现了治疗创新与商业性机会在治疗方法类型、药物类别、给药途径、分销管道和终端用户等各个层面的交汇点。对治疗方法类型的检验揭示了一个多面向的格局，其中吸入疗法、注射剂和口服药物各自发挥不同的作用。在吸入疗法中，干粉吸入器、定量吸入器和雾化器各自展现出不同的给药方案。干粉吸入器可细分为多剂量型和单剂量型，而雾化器则分为喷射式、网式和超音波技术。注射剂包括氨茶碱类药物、生物製剂和全身性糖皮质激素，其中生物製剂可细分为美泊利单抗、Omalizumab和瑞利珠单抗等药物。口服药物包括抗胆碱能药物、支气管扩张剂、联合治疗和皮质类固醇。抗胆碱能药物分为长效和短效两种类型，支气管扩张剂分为长效和短效β受体激动剂，皮质类固醇有吸入剂和全身给药剂两种剂型。

美洲、欧洲、中东和非洲以及亚太地区在监管、支付方和基础设施方面的区域差异如何影响采用趋势和获取策略？

区域趋势显着影响全球支气管痉挛药物的采纳、报销和临床应用。在美洲，与保险公司的密切合作、对降低住院率疗效的重视以及先进吸入装置的广泛应用，往往是推动临床应用的主要因素。该地区的市场进入策略通常优先考虑获取可靠的真实世界数据（REW）以及为呼吸科专家和基层医疗网络开展相关人员教育。在欧洲、中东和非洲，监管的多样性和报销系统的差异导致了多种多样的准入途径。区域医疗技术评估要求和采购惯例制定个人化的实证文件和弹性价格设定方法。同时，在亚太地区，数位医疗的快速发展、对国内生产能力的日益重视以及支付方成熟度的差异，正在影响着给药途径和分销渠道的选择，其中在线药房和居家照护服务在某些市场正迅速扩张。

製药、医疗设备和数位领域新参与企业的竞争行为分析：以合作、证据产生和製造敏捷性为差异化因素

支气管痉挛治疗领域的竞争格局呈现出多元化的态势，既有成熟的製药和医疗设备公司，也有新兴的专业研发企业，以及数量不断增长的数位医疗参与企业。拥有广泛呼吸系统产品系列的成熟企业往往透过整合製剂、医疗设备工程和全球分销等能力来维持市场地位，而小规模的专业公司则专注于独特的作用机制和差异化的给药技术，力求在细分市场中占据一席之地。医疗设备和生物製药研发企业之间日益密切的合作，正在催生旨在提高患者用药依从性和改善临床疗效的综合解决方案。

针对製造商和医疗保健提供者的具体策略行动，以加强供应韧性、促进用药依从性、创建引人注目的真实世界数据 (REW) 并加快获取途径。

产业领导者应优先考虑一系列兼顾临床价值和商业性韧性的实质措施。首先，应实现关键零件和原材料筹资策略的多元化，以降低关税和地缘政治动盪带来的风险，并评估近岸外包和双重采购的机会，以缩短前置作业时间。其次，应投资开发医疗设备的易用性和用药依从性支持工具，并将客观的用药依从性指标和病患教育融入产品中，以改善治疗效果并提高支付方的接受度。第三，应制定严谨的真实世界证据产生计划，以收集符合支付方要求的具有临床意义的终点和卫生经济学结果，从而促进获得有利的准入决策。

我们将以透明的方式解释一种多来源调查方法，该方法结合了临床医生的见解、文献整合和交叉检验分析，以得出严谨的行业知识。

本分析采用定性和定量相结合的研究途径，以确保对临床实践、医疗设备应用、支付方行为和供应趋势进行全面、多角度的洞察。主要调查包括对呼吸科医生、呼吸科护理师、采购经理和报销专家的结构化访谈，以了解他们对治疗方法选择、医疗设备易用性和获取障碍的实际观点。次要证据来自同行评审的临床文献、监管指导文件、医疗设备性能规范和已发布的临床指南，用于阐释主要研究结果并验证基于机制的检验。

我们简洁地整合了治疗、营运和政策的趋势，重点强调了将创新转化为临床影响和商业性成功的策略重点。

总之，支气管痉挛的治疗正在经历重大变革，这主要得益于标靶治疗、给药技术和医疗服务模式的进步。这些变革为改善患者预后创造了机会，具体体现在：更精准的治疗方法与疾病表型匹配、透过先进的吸入和雾化系统实现更可靠的药物输送，以及加强对患者用药依从性的监测。同时，贸易政策的变化和区域监管差异等宏观经济因素迫使企业更加谨慎地审视其生产、采购和打入市场策略。成功的企业将是那些能够将临床创新与营运韧性相结合，并创造符合支付方期望的实证医学证据的企业。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 按治疗类型分類的支气管痉挛治疗市场

  • 吸入疗法
    • 干粉吸入器
      • 多剂量干粉吸入剂
      • 单剂量干粉吸入器
    • 定量吸入器
    • 喷雾器
      • 喷射式雾化器
      • 筛孔式喷雾器
      • 超音波雾化器
  • 注射药物
    • 氨茶碱
    • 生物製药
      • 美泊利单抗
      • Omalizumab
      • 雷利兹玛
    • 全身性类固醇
  • 口服药物
    • 抗胆碱能药物
      • 长效抗胆碱能药物
      • 短效抗胆碱能药物
    • 支气管扩张剂
      • 长效β-激动剂
      • 短效β-激动剂
    • 联合治疗
    • 皮质类固醇
      • 吸入性类固醇
      • 全身性类固醇

第九章 支气管痉挛治疗市场：依药物类别划分

  • 抗胆碱能药物
  • β-激动剂
  • 皮质类固醇
    • 吸入性皮质类固醇
    • 全身性皮质类固醇
  • 白三烯调节剂
    • Montelukast
    • 札菲尔·卢卡斯特
    • 吉留顿

第十章 支气管痉挛治疗市场：依给药途径划分

  • 吸入
    • 气雾剂
    • 干粉
    • 喷雾器
  • 注射药物
    • 肌肉内部
    • 静脉
    • 皮下
  • 口服
    • 胶囊
    • 糖浆
    • 药片
  • 经皮
    • 凝胶
    • 修补

第十一章 支气管痉挛治疗市场：依通路划分

  • 在线的
  • 离线

第十二章 支气管痉挛治疗市场：依最终使用者划分

  • 门诊手术中心
  • 诊所
  • 居家照护
  • 医院

第十三章 支气管痉挛治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 支气管痉挛治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 支气管痉挛治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国支气管痉挛治疗市场

第十七章：中国支气管痉挛治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Amphastar Pharmaceuticals, Inc
  • Bayer AG
  • CH Boehringer Sohn AG & Co. KG
  • CHIESI Farmaceutici SpA
  • Cipla Limited
  • GlaxoSmithKline plc
  • Grifols, SA
  • Lybrate, Inc.
  • Merck KGaA
  • Novartis AG
  • Orion Corporation
  • Pfizer Inc
  • Temple University Health System, Inc.
  • Teva Pharmaceutical Industries Ltd
  • Vectura Group Ltd by Philip Morris International Inc.
  • Viatris Inc.
Product Code: MRR-3204321AF1B0

The Bronchial Spasms Treatment Market was valued at USD 323.86 million in 2025 and is projected to grow to USD 337.25 million in 2026, with a CAGR of 4.50%, reaching USD 440.77 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 323.86 million
Estimated Year [2026] USD 337.25 million
Forecast Year [2032] USD 440.77 million
CAGR (%) 4.50%

An authoritative overview of bronchial spasm clinical imperatives, therapeutic diversity, patient needs, and stakeholder decision drivers in modern care pathways

Bronchial spasms are episodic but frequently recurrent constrictive events of the lower airways that impose significant clinical burden on patients and clinical pathways. The pathophysiology involves hyperreactive airways with smooth muscle constriction, mucosal edema, and variable inflammatory processes that require rapid symptom relief as well as strategies to prevent recurrence. Clinicians balance acute management with long-term modulation of airway inflammation, and this balance shapes therapeutic choices across numerous care settings. As a result, the treatment landscape includes device-based delivery systems, injectable biologics and systemic agents, and oral therapies that address different mechanistic targets.

Against this clinical backdrop, stakeholders must navigate device usability, adherence dynamics, regulatory expectations, and evolving reimbursement environments that influence product adoption. Patients increasingly demand treatments that minimize exacerbation risk while preserving quality of life, and payers prioritize therapies that reduce hospital encounters and downstream costs. Consequently, industry participants are under pressure to demonstrate real-world effectiveness, patient-centered design, and cost-effectiveness in order to secure favorable uptake across ambulatory clinics, hospital systems, and home-care settings. This introduction frames the subsequent sections by highlighting the intersection of clinical need, therapeutic diversity, and commercial imperatives.

How precision therapeutics, advanced inhalation platforms, and care model evolution are reshaping clinical choices and commercial pathways for bronchial spasm management

Recent years have seen transformative shifts in bronchial spasms treatment driven by simultaneous advances in therapeutic modalities and care delivery models. On the therapeutic front, precise biologic agents and optimized inhalation technologies have broadened the clinical toolkit, allowing more tailored interventions for phenotypically distinct patient cohorts. Complementing pharmacologic progress, device innovation in powder and aerosol delivery has emphasized dosing accuracy, ease of use, and adherence support, which together are shifting how clinicians select and prescribe therapies. These changes are amplified by greater integration of digital adherence tools and remote monitoring, enabling longitudinal patient management beyond episodic clinic encounters.

Regulatory and reimbursement environments have evolved in parallel, with payers increasingly requesting robust real-world evidence and value-based outcomes that demonstrate reductions in acute care utilization. Meanwhile, supply chain resilience and manufacturing agility have gained prominence due to prior disruptions, prompting sponsors to diversify sourcing and localize critical components. In sum, the landscape is moving toward personalized, evidence-driven care pathways that couple targeted therapies with advanced delivery systems and data-rich performance measurement, reshaping clinical practice and commercial strategies alike.

Assessment of the practical effects of 2025 United States tariff changes on supply chains, manufacturing economics, procurement strategies, and clinical continuity for bronchial spasm treatments

The cumulative effects of the United States tariff adjustments implemented in 2025 have introduced practical implications for participants across the bronchial spasms treatment ecosystem. Tariff-driven increases in the cost of active pharmaceutical ingredients, device components such as metering valves and specialized polymers, and imported manufacturing equipment have exerted upward pressure on production economics. Sponsors and contract manufacturers have responded by re-examining supplier contracts, accelerating dual-sourcing strategies, and in some cases relocating critical assembly steps closer to key markets to mitigate exposure to trade policy volatility.

Beyond direct cost impacts, tariffs have influenced strategic prioritization of capital expenditure, with manufacturers weighing the returns of investing in localized production against the benefits of maintaining globalized supply chains. Payers and providers have also felt secondary effects; procurement negotiations now factor in longer lead times and potential price variability, which can affect formulary positioning and purchasing cadence. Looking forward, the industry is adapting through a combination of contractual hedging, increased inventory buffers for critical components, and collaborative engagements with logistics partners to preserve continuity of care without compromising regulatory compliance or clinical quality standards.

In-depth segmentation analysis linking therapeutic modalities, delivery formats, drug classes, channels, and care settings to clinical adoption and commercialization levers

A granular segmentation lens clarifies where therapeutic innovation and commercial opportunity intersect across treatment types, drug classes, administration routes, distribution channels, and end users. Examining treatment type reveals a multi-modal landscape in which inhalation therapy, injectable medications, and oral medications play distinct roles. Within inhalation therapy, dry powder inhalers, metered dose inhalers, and nebulizers represent differentiated delivery profiles; dry powder devices subdivide into multi-dose and single-dose formats, while nebulizers split into jet, mesh, and ultrasonic technologies. Injectable options include aminophylline, biologics, and systemic steroids, with biologics further differentiated by agents such as mepolizumab, omalizumab, and reslizumab. Oral medications encompass anticholinergics, bronchodilators, combination therapies, and corticosteroids, with anticholinergics separating into long-acting and short-acting variants and bronchodilators into long-acting and short-acting beta agonists, while corticosteroids appear as inhaled and systemic formulations.

When viewed by drug class, distinctions among anticholinergics, beta agonists, corticosteroids, and leukotriene modifiers influence prescribing patterns and payer assessments, and subclasses within each category affect clinical positioning. Route of administration further refines opportunity sets: inhalation modalities span aerosol, dry powder, and nebulization approaches; injectables cover intramuscular, intravenous, and subcutaneous routes; oral therapies are delivered in capsule, syrup, or tablet formats; and transdermal options include gels and patches. Distribution channel dynamics shape access and patient experience, with clinics, hospital pharmacies, online pharmacies, and retail pharmacies each subdivided by practice type or retail model. Finally, end-user segmentation highlights distinct care settings-ambulatory surgical centers, clinics, home care, and hospitals-with outpatient and specialist clinics as key subsegments and private and public hospital distinctions that affect procurement and clinical protocols. Together, these segmentation layers inform product design, commercialization tactics, and evidence generation priorities by aligning therapeutic attributes to the operational realities of each channel and user type.

How regional regulatory, payer, and infrastructure differences across the Americas, Europe Middle East & Africa, and Asia-Pacific shape adoption dynamics and access strategies

Regional dynamics materially influence how bronchial spasms therapies are adopted, reimbursed, and integrated into clinical practice across the globe. In the Americas, clinical adoption tends to be driven by strong payer engagement, emphasis on outcomes that reduce hospital utilization, and widespread availability of advanced inhalation devices; market access strategies there typically prioritize robust real-world evidence and stakeholder education for pulmonologists and primary care networks. In Europe, Middle East & Africa, regulatory diversity and heterogeneous reimbursement systems create a mosaic of access pathways, where localized health technology assessment requirements and procurement practices necessitate tailored evidence dossiers and flexible pricing approaches. Meanwhile, in the Asia-Pacific region, rapid uptake of digital health, a growing emphasis on domestic manufacturing capability, and varied payer maturity influence both route-of-administration preferences and distribution channel choices, with online pharmacies and home-care services expanding rapidly in certain markets.

Across all regions, differences in clinician training, patient preferences, and healthcare infrastructure shape which delivery systems and therapeutic classes gain traction. These regional contrasts underscore the need for differentiated commercialization plans, adaptive clinical support programs, and supply chain footprints that align with regulatory timelines and local procurement norms. Consequently, strategic planning must incorporate region-specific evidence generation, stakeholder engagement, and logistical arrangements to ensure treatment innovations translate into measurable improvements in patient outcomes and care continuity.

Analysis of competitive behaviors among pharmaceutical, device, and digital entrants emphasizing collaboration, evidence generation, and manufacturing agility as differentiators

Competitive dynamics in the bronchial spasms treatment space reflect a blend of established pharmaceutical and device players, emerging specialty developers, and a growing cohort of digital health entrants. Incumbent firms with broad respiratory portfolios tend to leverage integrated capabilities-spanning formulation, device engineering, and global distribution-to sustain market presence, while smaller specialist companies focus on novel mechanisms or differentiated delivery technologies to carve niche positions. Collaboration between device and biologic developers has become more frequent, producing combination solutions that aim to improve adherence and clinical outcomes.

Strategic priorities among companies include strengthening clinical pipelines with targeted indications, investing in user-centric device design to reduce misuse, and generating robust real-world evidence to satisfy payer demands. Manufacturing agility and regulatory savvy are also competitive differentiators, as firms that can localize production, expedite regulatory submissions, and provide post-market safety data tend to achieve smoother market entry. Mergers, strategic partnerships, and licensing arrangements remain important mechanisms for accelerating access to complementary capabilities, while commercialization success often hinges on the depth of clinical stakeholder relationships and the ability to demonstrate measurable reductions in acute care episodes.

Concrete strategic actions for manufacturers and providers to strengthen supply resilience, drive adherence, generate compelling real-world evidence, and accelerate access

Industry leaders should prioritize a set of pragmatic actions that align clinical value with commercial resilience. First, diversify sourcing strategies for critical components and raw materials to reduce exposure to tariff-related and geostrategic disruptions, while evaluating opportunities for nearshoring or dual-sourcing to shorten lead times. Second, invest in device usability and adherence support tools, integrating objective adherence measures and patient education into product offerings to improve therapeutic outcomes and payer receptivity. Third, develop rigorous real-world evidence generation plans that capture clinically meaningful endpoints and health economic outcomes aligned with payer requirements to facilitate favorable access decisions.

Additionally, forge collaborative partnerships with healthcare systems and specialty clinics to streamline patient pathways and collect longitudinal outcome data that demonstrate value. Enhance regulatory engagement early to align clinical development with regional submission expectations, and consider staged rollouts that prioritize high-value care settings. Finally, adopt flexible pricing and contracting approaches, including outcome-based arrangements where appropriate, to lower payer barriers and accelerate adoption. Implementing these strategies will help organizations translate scientific advances into durable clinical impact and sustainable commercial performance.

Transparent description of multi-source research techniques combining clinician insights, literature synthesis, and cross-validated analysis to produce rigorous industry findings

The research approach underpinning this analysis combined qualitative and quantitative techniques to ensure balanced, multi-source insight into clinical practice, device adoption, payer behavior, and supply dynamics. Primary research included structured interviews with pulmonologists, respiratory nurses, procurement leaders, and reimbursement specialists to capture frontline perspectives on treatment selection, device usability, and access barriers. Secondary evidence was synthesized from peer-reviewed clinical literature, regulatory guidance documents, device performance specifications, and published clinical guidelines to contextualize primary findings and to validate mechanistic rationale.

Analytical rigor was achieved through cross-validation of themes across data sources, targeted case studies of representative product launches, and scenario-based analysis of supply chain and policy shocks. Limitations of the methodology are acknowledged: stakeholder interviews may reflect practice variation, and publicly available literature may lag the most recent commercial developments. To mitigate these constraints, the study applied conservative interpretation of emerging trends and prioritized triangulated findings that appeared consistently across independent sources. Where relevant, the research identifies evidence gaps and recommends follow-up primary studies to address critical uncertainties.

Concise synthesis of therapeutic, operational, and policy dynamics highlighting strategic priorities for converting innovation into clinical impact and commercial success

In summary, bronchial spasms treatment is undergoing a phase of substantive evolution driven by advances in targeted therapeutics, delivery technologies, and care delivery models. These shifts create opportunities to improve patient outcomes through better matching of therapeutic modality to phenotype, more reliable delivery through refined inhalation and nebulization systems, and enhanced adherence monitoring. At the same time, macro forces such as trade policy changes and regional regulatory heterogeneity require companies to be more deliberate in their manufacturing, sourcing, and market-entry strategies. Successful organizations will be those that combine clinical innovation with operational resilience and evidence generation tailored to payer expectations.

Decision-makers should view the current environment as one where coordinated investments across product design, clinical evidence programs, and supply chain architecture can yield competitive advantage. By aligning technical development with stakeholder needs and regional access dynamics, leaders can convert scientific promise into reproducible clinical benefit and sustainable commercial performance. The following call to action outlines options for acquiring the full report and arranging targeted briefings to translate these insights into immediate strategic plans.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bronchial Spasms Treatment Market, by Treatment Type

  • 8.1. Inhalation Therapy
    • 8.1.1. Dry Powder Inhalers
      • 8.1.1.1. Multi-Dose Dpi
      • 8.1.1.2. Single-Dose Dpi
    • 8.1.2. Metered Dose Inhalers
    • 8.1.3. Nebulizers
      • 8.1.3.1. Jet Nebulizers
      • 8.1.3.2. Mesh Nebulizers
      • 8.1.3.3. Ultrasonic Nebulizers
  • 8.2. Injectable Medications
    • 8.2.1. Aminophylline
    • 8.2.2. Biologics
      • 8.2.2.1. Mepolizumab
      • 8.2.2.2. Omalizumab
      • 8.2.2.3. Reslizumab
    • 8.2.3. Systemic Steroids
  • 8.3. Oral Medications
    • 8.3.1. Anticholinergics
      • 8.3.1.1. Long-Acting Anticholinergics
      • 8.3.1.2. Short-Acting Anticholinergics
    • 8.3.2. Bronchodilators
      • 8.3.2.1. Long-Acting Beta Agonists
      • 8.3.2.2. Short-Acting Beta Agonists
    • 8.3.3. Combination Therapies
    • 8.3.4. Corticosteroids
      • 8.3.4.1. Inhaled Steroids
      • 8.3.4.2. Systemic Steroids

9. Bronchial Spasms Treatment Market, by Drug Class

  • 9.1. Anticholinergics
  • 9.2. Beta Agonists
  • 9.3. Corticosteroids
    • 9.3.1. Inhaled Corticosteroids
    • 9.3.2. Systemic Corticosteroids
  • 9.4. Leukotriene Modifiers
    • 9.4.1. Montelukast
    • 9.4.2. Zafirlukast
    • 9.4.3. Zileuton

10. Bronchial Spasms Treatment Market, by Route Of Administration

  • 10.1. Inhalation
    • 10.1.1. Aerosol
    • 10.1.2. Dry Powder
    • 10.1.3. Nebulization
  • 10.2. Injectable
    • 10.2.1. Intramuscular
    • 10.2.2. Intravenous
    • 10.2.3. Subcutaneous
  • 10.3. Oral
    • 10.3.1. Capsule
    • 10.3.2. Syrup
    • 10.3.3. Tablet
  • 10.4. Transdermal
    • 10.4.1. Gel
    • 10.4.2. Patch

11. Bronchial Spasms Treatment Market, by Distribution Channel

  • 11.1. Online
  • 11.2. Offline

12. Bronchial Spasms Treatment Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Clinics
  • 12.3. Home Care
  • 12.4. Hospitals

13. Bronchial Spasms Treatment Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Bronchial Spasms Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Bronchial Spasms Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Bronchial Spasms Treatment Market

17. China Bronchial Spasms Treatment Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Amphastar Pharmaceuticals, Inc
  • 18.6. Bayer AG
  • 18.7. C.H. Boehringer Sohn AG & Co. KG
  • 18.8. CHIESI Farmaceutici S.p.A.
  • 18.9. Cipla Limited
  • 18.10. GlaxoSmithKline plc
  • 18.11. Grifols, S.A.
  • 18.12. Lybrate, Inc.
  • 18.13. Merck KGaA
  • 18.14. Novartis AG
  • 18.15. Orion Corporation
  • 18.16. Pfizer Inc
  • 18.17. Temple University Health System, Inc.
  • 18.18. Teva Pharmaceutical Industries Ltd
  • 18.19. Vectura Group Ltd by Philip Morris International Inc.
  • 18.20. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BRONCHIAL SPASMS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BRONCHIAL SPASMS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MULTI-DOSE DPI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MULTI-DOSE DPI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MULTI-DOSE DPI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SINGLE-DOSE DPI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SINGLE-DOSE DPI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SINGLE-DOSE DPI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY METERED DOSE INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY METERED DOSE INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY METERED DOSE INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY JET NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY JET NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY JET NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MESH NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MESH NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MESH NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ULTRASONIC NEBULIZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AMINOPHYLLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AMINOPHYLLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AMINOPHYLLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEPOLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEPOLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MEPOLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY OMALIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY OMALIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY OMALIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY RESLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY RESLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY RESLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING ANTICHOLINERGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING ANTICHOLINERGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LONG-ACTING BETA AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SHORT-ACTING BETA AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COMBINATION THERAPIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED STEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED STEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED STEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC STEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BETA AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BETA AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BETA AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALED CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYSTEMIC CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MONTELUKAST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MONTELUKAST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY MONTELUKAST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZAFIRLUKAST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZAFIRLUKAST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZAFIRLUKAST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZILEUTON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZILEUTON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ZILEUTON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AEROSOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AEROSOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AEROSOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYRUP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYRUP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SYRUP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY GEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY GEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY GEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 195. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 197. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 199. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 200. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 201. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 202. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 203. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 204. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 205. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 206. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 207. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, 2018-2032 (USD MILLION)
  • TABLE 208. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 210. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 211. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 212. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2032 (USD MILLION)
  • TABLE 213. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. AMERICAS BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 218. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 220. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 222. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 224. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 226. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 228. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, 2018-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 232. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2032 (USD MILLION)
  • TABLE 234. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, 2018-2032 (USD MILLION)
  • TABLE 240. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 242. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 244. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 246. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 248. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, 2018-2032 (USD MILLION)
  • TABLE 250. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 252. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 254. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 256. LATIN AMERICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPE, MIDDLE EAST & AFRICA BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRY POWDER INHALERS, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY NEBULIZERS, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 285. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL MEDICATIONS, 2018-2032 (USD MILLION)
  • TABLE 286. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, 2018-2032 (USD MILLION)
  • TABLE 287. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY BRONCHODILATORS, 2018-2032 (USD MILLION)
  • TABLE 288. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 289. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 290. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY LEUKOTRIENE MODIFIERS, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPE BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST BRONCHIAL SPASMS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 300. MIDDLE EAST BR